Celcuity Inc. (CELC)

NCM – Цена в реальном времени. Валюта: USD

124.68

-0.96 (-0.76%)

При закрытии: May 12, 2026, 4:00 PM EDT

125.00

+0.32 (0.26%)

До открытия: May 13, 2026, 8:31 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Celcuity Inc. (CELC)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Celcuity Inc. (CELC)

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

Why Is Celcuity Stock Rallying Today?

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Celcuity: Best-In-Class Potential With 2-3x Upside If Mutant Data Delivers

Why Celcuity Stock Popped Today

Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Celcuity Appoints Charles Romp to its Board of Directors

Search stocks

Celcuity Inc. (CELC)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Celcuity Inc. (CELC)

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

Why Is Celcuity Stock Rallying Today?

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Celcuity: Best-In-Class Potential With 2-3x Upside If Mutant Data Delivers

Why Celcuity Stock Popped Today

Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Celcuity Appoints Charles Romp to its Board of Directors